Clinical Trial Update: CT-322 in Treating Patients With Recurrent Glioblastoma Multiforme and Combination Therapy With Irinotecan [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update evaluating CT-322 with irinotecan for recurrent glioblastoma multiforme; sponsored by Adnexus (a Bristol-Myers Squibb R&D company)…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Brain Tumors
• Central Nervous System Neoplasms
• Glioblastoma Multiforme

Drugs mentioned

• CT-322
• Irinotecan (Irinotecan)

Snippet

Sponsor: Adnexus, A Bristol-Myers Squibb R&D Company | Conditions: Brain and Central Nervous System Tumors, Recurrent Glioblastoma Multiforme | Phase 2 | Status: UNKNOWN